| ²é¿´: 951 | »Ø¸´: 2 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßwfpzmd360073½«ÔùËÍÄú 30 ¸ö½ð±Ò | ||
wfpzmd360073½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÎÄÏ×ÇóÖú£¬¼±¼±¼±£¡£¡£¡£¡ ÒÑÓÐ1È˲ÎÓë
|
|
|
ÇóÖúһƪÁÙ´²Ñо¿ÎÄÕ£¬Â·¹ýµÄ´óÉñÇë°ï棬лл£¡£¡£¡£¡ Á´½Ó£ºhttps://pubmed.ncbi.nlm.nih.gov/38823410/ doi: 10.1016/S1470-2045(24)00159-1. Epub 2024 May 29 ÌâÄ¿£ºBL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study |
» ²ÂÄãϲ»¶
Çë½Ìõ£°·ËõºÏ·´Ó¦
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸´óÁ¬Àí¹¤ÖÆÒ©¹¤³Ìר˶086002£¬±¾¿Æ211£¬×Ü·Ö342
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ285È˻ظ´
ÖÆÒ©¹¤³ÌרҵÕÐÊÕµ÷¼Á£¬ÒªÇó¹ý¹ú¼ÒÏß
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
¿ÉÄÜÉϲ»Á˰¶£¿ÓÐÌõ¼þµÄ¿ÉÒÔ¿¼ÂÇÆäËû³ö·
ÒѾÓÐ0È˻ظ´

zyqchem
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 159 (¸ßÖÐÉú)
- ½ð±Ò: 286101
- ºì»¨: 553
- ɳ·¢: 1964
- Ìû×Ó: 55192
- ÔÚÏß: 11867.1Сʱ
- ³æºÅ: 3786654
- ×¢²á: 2015-04-04
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2025-11-26 12:01:26
tfang
ľ³æÖ®Íõ (ÎÄ̳¾«Ó¢)
ľ³æ008Ö®´óÀÁ³æ
- Ó¦Öú: 109 (¸ßÖÐÉú)
- ¹ó±ö: 0.002
- ½ð±Ò: 125988
- É¢½ð: 8530
- ºì»¨: 155
- ɳ·¢: 3
- Ìû×Ó: 47997
- ÔÚÏß: 2145.9Сʱ
- ³æºÅ: 529162
- ×¢²á: 2008-03-20
- ÐÔ±ð: GG
- רҵ: ÂÌÉ«Óлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
ͨ¹ýÍøÅÌ·ÖÏíµÄÎļþ£ºBL-B01D1, a first-in-class EGFR¨CHER3 bispecific antibody¨Cdrug conjugate, in patients with locally advanced or metastatic solid tumours a first-in-human, open-label, multicentre, phase 1 study._20251127_083531.pdf Á´½Ó: https://pan.baidu.com/s/1Fjp97hdJLNbLM_NIE6nOHQ?pwd=bpib ÌáÈ¡Âë: bpib ¸´ÖÆÕâ¶ÎÄÚÈݺó´ò¿ª°Ù¶ÈÍøÅÌÊÖ»úApp£¬²Ù×÷¸ü·½±ãŶ |

3Â¥2025-11-27 08:35:43













»Ø¸´´ËÂ¥